$NSPR News

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

Full Transcript: InspireMD Q2 2026 Earnings Call

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

InspireMD Inc (NSPR) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges While ...

InspireMD, Inc. Q2 2026 Earnings Call Summary

InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript

InspireMD Reports Second Quarter 2026 Financial Results

InspireMD Q2 EPS $(0.17) Beats $(0.19) Estimate, Sales $1.771M Miss $2.133M Estimate

InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates

InspireMD to Announce Second Quarter 2026 Financial Results

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures

InspireMD Announces 30-Day Outcomes From CGUARDIANS II Clinical Trial Of CGuard Prime 80cm Implant For Use In Transcarotid Artery Revascularization Procedures

InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures

InspireMD Announces First Patient Enrolled In CGUARDIANS III Pivotal Study Of SwitchGuard Neuro Protection System, For Use With CGuard Prime 80 cm Stent Platform, In TCAR Procedures

InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript